AR118560A2 - Métodos y composiciones que comprenden polipéptidos recombinantes purificados - Google Patents
Métodos y composiciones que comprenden polipéptidos recombinantes purificadosInfo
- Publication number
- AR118560A2 AR118560A2 ARP200100914A ARP200100914A AR118560A2 AR 118560 A2 AR118560 A2 AR 118560A2 AR P200100914 A ARP200100914 A AR P200100914A AR P200100914 A ARP200100914 A AR P200100914A AR 118560 A2 AR118560 A2 AR 118560A2
- Authority
- AR
- Argentina
- Prior art keywords
- less
- methods
- purified recombinant
- recombinant polypeptides
- compositions including
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 241000699800 Cricetinae Species 0.000 abstract 2
- 241000699802 Cricetulus griseus Species 0.000 abstract 2
- 210000001672 ovary Anatomy 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan polipéptidos recombinantes purificados aislados de células huésped de ovario de hámster chino, incluyendo anticuerpos tales como anticuerpos terapéuticos y métodos de preparación y uso de tales polipéptidos. Reivindicación 1: Una composición que comprende un anticuerpo monoclonal anti-IL13 purificado de células huésped de ovario de hámster chino, en donde la composición comprende el anticuerpo anti-IL13 y una cantidad residual de hámster PLBL2, en donde la cantidad de PLBL2 de hámster es inferior a 20 ng/mg o inferior a 15 ng/mg o inferior a 10 ng/mg o inferior a 8 ng/mg o inferior a 5 ng/mg o inferior a 3 ng/mg o inferior a 2 ng/mg o inferior a 1 ng/mg o inferior a 0,5 ng/mg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361877517P | 2013-09-13 | 2013-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118560A2 true AR118560A2 (es) | 2021-10-20 |
Family
ID=52666315
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140103417A AR097651A1 (es) | 2013-09-13 | 2014-09-12 | Métodos y composiciones que comprenden polipéptidos recombinantes purificados |
ARP200100914A AR118560A2 (es) | 2013-09-13 | 2020-04-01 | Métodos y composiciones que comprenden polipéptidos recombinantes purificados |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140103417A AR097651A1 (es) | 2013-09-13 | 2014-09-12 | Métodos y composiciones que comprenden polipéptidos recombinantes purificados |
Country Status (18)
Country | Link |
---|---|
US (7) | US9920120B2 (es) |
EP (3) | EP4331605A3 (es) |
JP (4) | JP6751344B2 (es) |
KR (2) | KR102373930B1 (es) |
CN (1) | CN105722532A (es) |
AR (2) | AR097651A1 (es) |
AU (2) | AU2014318615B2 (es) |
BR (1) | BR112016004413A2 (es) |
CA (2) | CA2921999C (es) |
HK (1) | HK1225988A1 (es) |
IL (1) | IL244149A0 (es) |
MX (3) | MX2016003202A (es) |
MY (2) | MY176026A (es) |
NZ (3) | NZ718144A (es) |
RU (1) | RU2671481C2 (es) |
SG (2) | SG10201802525QA (es) |
WO (1) | WO2015038888A1 (es) |
ZA (4) | ZA201601965B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9994609B2 (en) | 2013-03-15 | 2018-06-12 | Biogen Ma Inc. | Hydrophobic interaction protein chromatography under no-salt conditions |
NZ718144A (en) * | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
TW201702380A (zh) | 2015-02-27 | 2017-01-16 | 再生元醫藥公司 | 宿主細胞蛋白質修飾 |
WO2017031476A2 (en) * | 2015-08-20 | 2017-02-23 | Genentech, Inc. | Purification of fkpa and uses thereof for producing recombinant polypeptides |
BR112018001511A2 (pt) * | 2015-08-21 | 2018-09-18 | Hoffmann La Roche | ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano |
CN107835819A (zh) | 2015-08-21 | 2018-03-23 | 豪夫迈·罗氏有限公司 | 在亲和层析中减少宿主细胞蛋白的方法 |
MX2018012550A (es) * | 2016-04-14 | 2019-07-08 | Lonza Ag | Composiciones y metodos para la deteccion de proteinas de celulas huesped. |
EP3487868A4 (en) * | 2016-07-25 | 2020-07-29 | Cephalon, Inc. | WASHING PAD FOR AFFINITY CHROMATOGRAPHY |
BR112019000872A2 (pt) | 2016-08-16 | 2019-04-30 | Regeneron Pharmaceuticals, Inc. | métodos para quantificar anticorpos individuais de uma mistura |
EP4389757A2 (en) | 2016-09-07 | 2024-06-26 | GlaxoSmithKline Intellectual Property Development Limited | Methods for purifying antibodies |
BR112019004938A2 (pt) * | 2016-10-06 | 2019-06-25 | Glaxosmithkline Ip Dev Ltd | anticorpo igg4 variante, linhagem celular, métodos para modificação de um anticorpo igg para reduzir a ligação a uma impureza de processo e para produção de um anticorpo igg4 com ligação reduzida à proteína de célula hospedeira, e, composição. |
CA3039788A1 (en) | 2016-10-25 | 2018-05-03 | Regeneron Pharmaceuticals, Inc. | Methods and systems for chromatography data analysis |
MY197200A (en) | 2016-12-23 | 2023-05-31 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
WO2019060062A1 (en) | 2017-09-19 | 2019-03-28 | Regeneron Pharmaceuticals Inc. | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM |
TW202003555A (zh) * | 2018-03-07 | 2020-01-16 | 英商葛蘭素史克智慧財產發展有限公司 | 用於純化重組多肽之方法 |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
EP3826743A4 (en) * | 2018-07-25 | 2022-09-14 | Merck Sharp & Dohme Corp. | METHODS FOR SEPARATION OF HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC METHODS |
WO2020153390A1 (ja) | 2019-01-23 | 2020-07-30 | 第一三共株式会社 | 活性炭材料を使用する工程を含む抗体精製方法 |
WO2020157749A1 (en) * | 2019-01-29 | 2020-08-06 | Bnai Zion Medical Center | Anti il-17 antibody for use in treating chronic spontaneous urticaria |
CN114555622A (zh) * | 2019-10-04 | 2022-05-27 | 默克专利股份有限公司 | 蛋白质的纯化和病毒灭活 |
CN115023276A (zh) * | 2020-01-29 | 2022-09-06 | 默沙东有限公司 | 从抗-lag3抗体生产中分离宿主细胞脂肪酶的方法 |
JP2024517779A (ja) * | 2021-05-03 | 2024-04-23 | アジレント・テクノロジーズ・インク | キメラ免疫原および特定のエピトープに対するポリクローナル抗体の作製方法 |
WO2023215750A2 (en) * | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
WO2024137702A1 (en) * | 2022-12-19 | 2024-06-27 | Eli Lilly And Company | Methods of reducing contaminants in protein purification |
CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
Family Cites Families (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1319315A (en) | 1969-06-19 | 1973-06-06 | Citizen Watch Co Ltd | Calendar timepiece |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3422247A1 (de) | 1984-06-15 | 1985-12-19 | Pfeifer & Langen, 5000 Köln | Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US4847745A (en) | 1988-11-16 | 1989-07-11 | Sundstrand Corp. | Three phase inverter power supply with balancing transformer |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5011778A (en) | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ZA9010190B (en) | 1989-12-20 | 1991-08-28 | Schering Corp | Antibody antagonists of human interleukin-4 |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
MD1652G2 (ro) | 1991-03-29 | 2001-12-31 | Sanofi-Synthelabo | Proteină cu activitate de tip citochină, ADN recombinant, codificator pentru această proteină, celule şi microorganisme transformate, vector de expresie, procedeu de obţinere a proteinei şi remediu care conţine această proteină |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5994514A (en) | 1991-08-14 | 1999-11-30 | Genentech, Inc. | Immunoglobulin variants |
US5965709A (en) | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5550045A (en) | 1992-05-15 | 1996-08-27 | Unilever Patent Holdings, B.V. | Cloning and expression of DNA encoding a ripening form of a polypeptide having rhamnogalcturonase activity |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
WO1994004680A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Human interleukin-13 |
US5596072A (en) | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
ATE175239T1 (de) | 1993-05-17 | 1999-01-15 | Genentech Inc | Sialidase defiziente zellen |
EP0721469B1 (en) | 1993-09-02 | 2000-01-05 | Trustees of Dartmouth College | Anti-gp39 antibodies and uses therefor |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6911530B1 (en) | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
CA2238080C (en) | 1995-10-23 | 2012-03-13 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
CA2243459C (en) | 1996-02-09 | 2002-09-17 | Basf Aktiengesellschaft | Human antibodies that bind human tnf.alpha. |
US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
ES2335365T3 (es) | 1996-11-27 | 2010-03-25 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina a. |
US6743604B1 (en) | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
GB9625899D0 (en) | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
BR9714523A (pt) | 1997-01-10 | 2000-05-02 | Biogen Inc | Tratamento de nefrite de lúpus com compostos anti-cd40l |
JP2002514201A (ja) | 1997-01-22 | 2002-05-14 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 凝固および腫瘍の処置のための組織因子の方法および組成物 |
US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US6482403B1 (en) | 1998-05-29 | 2002-11-19 | Heska Corporation | Caniney IL-13 immunoregulatory proteins and uses thereof |
US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
GB9820014D0 (en) | 1998-09-14 | 1998-11-04 | Cancer Res Campaign Tech | Receptor antagonists and uses thereof |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
DE19848026A1 (de) | 1998-10-17 | 2000-04-20 | Bayer Ag | Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
PT1141286E (pt) | 1998-12-14 | 2007-01-31 | Genetics Inst Llc | Cadeia de receptores de citocina |
US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
WO2000044407A2 (en) | 1999-02-01 | 2000-08-03 | Amgen Canada | Materials and methods to inhibit hodgkin and reed sternberg cell growth |
WO2001034645A2 (en) | 1999-11-11 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Mutated il-13 molecules and their uses |
US20100041039A1 (en) | 2000-01-15 | 2010-02-18 | Synageva Biopharma Corp. | Analysis of nucleic acid obtained from nucleated red blood cells |
AU4178601A (en) | 2000-02-24 | 2001-09-03 | Univ Washington | Humanized antibodies that sequester abeta peptide |
AU2001236073B2 (en) | 2000-03-03 | 2006-10-19 | Kyowa Kirin Co., Ltd. | Gene recombinant antibody and its fragment |
CN1323812A (zh) | 2000-05-16 | 2001-11-28 | 上海博德基因开发有限公司 | 一种新的多肽——人白细胞介素-13(il-13)受体11和编码这种多肽的多核苷酸 |
WO2002033073A1 (fr) | 2000-10-20 | 2002-04-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agoniste degrade |
WO2002055100A2 (en) | 2000-10-20 | 2002-07-18 | Genetics Institute, Llc | Method and composition for inhibition of tumor growth and enhancing an immune response |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
WO2003002144A1 (en) | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
US20030023555A1 (en) | 2001-07-26 | 2003-01-30 | Cashworks, Inc. | Method and system for providing financial services |
MXPA04001894A (es) | 2001-08-31 | 2005-09-08 | Kyowa Hakko Kogyo Kk | Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo. |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
WO2003035847A2 (en) | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
WO2003040164A2 (en) | 2001-11-07 | 2003-05-15 | Cytos Biotechnology Ag | Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases |
ATE417858T1 (de) | 2002-02-05 | 2009-01-15 | Genentech Inc | Proteinaufreinigung |
WO2003086451A1 (en) | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
US20040060102A1 (en) | 2002-04-10 | 2004-04-01 | Interspiro, Inc. | Garments for biological, chemical and fire protection |
EP1501369B1 (en) | 2002-04-26 | 2015-06-24 | Genentech, Inc. | Non-affinity purification of proteins |
EP1552462B1 (en) | 2002-06-14 | 2011-03-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods of treating and preventing colitis involving il-13 and nk-t cells |
TW200407162A (en) | 2002-08-30 | 2004-05-16 | Glaxo Group Ltd | Vaccine |
US20060104943A1 (en) | 2002-08-30 | 2006-05-18 | Claire Ashman | Vaccine comprising il-13 and an adjuvant |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
EP1596809B1 (en) | 2003-02-10 | 2010-05-26 | Applied Molecular Evolution, Inc. | Abeta binding molecules |
US7157276B2 (en) | 2003-06-20 | 2007-01-02 | Biogen Idec Inc. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
PT1703893E (pt) * | 2003-12-23 | 2012-06-01 | Genentech Inc | Novos anticorpos anti-il 13 e as respectivas utilizações |
TR201815885T4 (tr) | 2004-01-07 | 2018-11-21 | Novartis Vaccines & Diagnostics Inc | M-csf spesifik monoklonal antikorlar ve bunların kullanımı. |
WO2005071410A1 (en) | 2004-01-13 | 2005-08-04 | Tanox, Inc. | Detecting and quantifying host cell proteins in recombinant protein products |
WO2005075647A1 (en) | 2004-02-06 | 2005-08-18 | Nymox Corporation | Humanized antibody |
US20070190046A1 (en) | 2004-02-23 | 2007-08-16 | Eli Lilly And Company | Anti-abeta antibody |
EP1745141B2 (en) | 2004-05-04 | 2019-09-25 | Novo Nordisk Health Care AG | O-linked glycoforms of faktor vii and method to manufacture them |
US20070037966A1 (en) * | 2004-05-04 | 2007-02-15 | Novo Nordisk A/S | Hydrophobic interaction chromatography purification of factor VII polypeptides |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
NZ554520A (en) | 2004-10-22 | 2010-03-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
ES2434517T3 (es) | 2004-12-24 | 2013-12-16 | Commonwealth Scientific And Industrial Research Organisation | Composiciones y procedimientos pesticidas |
US8067182B2 (en) | 2005-03-11 | 2011-11-29 | Wyeth Llc | Method of weak partitioning chromatography |
CA2604877A1 (en) | 2005-04-11 | 2006-10-19 | J.P. Sercel Associates Inc. | Protein purification |
EP1896504B1 (en) | 2005-06-17 | 2012-11-21 | Wyeth LLC | Methods of purifying fc region containing antibodies |
JP3982545B2 (ja) | 2005-09-22 | 2007-09-26 | ダイキン工業株式会社 | 空気調和装置 |
AU2006296399B2 (en) * | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Il-13에 대항한 인간 항체 및 치료적 용도 |
CN102898519B (zh) | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
US7667557B2 (en) | 2005-12-06 | 2010-02-23 | Tdk Corporation | Thin-film bandpass filter using inductor-capacitor resonators |
KR101505201B1 (ko) | 2005-12-12 | 2015-03-24 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
RS52004B (en) | 2005-12-12 | 2012-04-30 | F. Hoffmann-La Roche Ag | ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION |
ES2382164T3 (es) | 2005-12-30 | 2012-06-05 | Merck Patent Gmbh | Anticuerpos anti-IL-6 que impiden la unión de la IL-6 en complejo con el IL-6R( ) a la GP130 |
US7563875B2 (en) | 2006-03-20 | 2009-07-21 | The United States of America as represented by the Sercretary of the Army | Recombinant chimeric human anti-botulinum antibodies |
KR20140071452A (ko) * | 2006-04-05 | 2014-06-11 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
CN101472947A (zh) | 2006-04-21 | 2009-07-01 | 惠氏公司 | 用于高通量筛选细胞系的方法 |
CL2007002070A1 (es) | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
WO2008036863A2 (en) | 2006-09-21 | 2008-03-27 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
CN101611054B (zh) | 2006-10-02 | 2013-12-25 | Ac免疫有限公司 | 针对淀粉状蛋白β的人源化抗体 |
PL2457929T3 (pl) | 2006-10-04 | 2016-12-30 | Test ELISA dla VEGF | |
US8383350B1 (en) | 2006-12-20 | 2013-02-26 | Merck Sharp & Dohme Corp. | Assay for detection of IL-10 antibodies |
CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
WO2008140455A1 (en) | 2007-05-15 | 2008-11-20 | Tanox, Inc. | Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies |
NZ601843A (en) | 2007-06-12 | 2014-01-31 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
EP2574345A1 (en) | 2007-06-12 | 2013-04-03 | AC Immune S.A. | Humanized antibodies to amyloid beta |
US9433922B2 (en) | 2007-08-14 | 2016-09-06 | Emd Millipore Corporation | Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same |
WO2009048539A2 (en) | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Monoclonal antibody |
BRPI0818621A8 (pt) | 2007-10-05 | 2018-01-30 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo |
EP2650308A3 (en) | 2007-10-05 | 2014-11-12 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
WO2009058769A1 (en) * | 2007-10-30 | 2009-05-07 | Schering Corporation | Purification of antibodies containing hydrophobic variants |
CA2718120A1 (en) | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
WO2009131643A1 (en) | 2008-04-21 | 2009-10-29 | Monabio, Inc. | Immunoassay for specific determination of s-adenosymethionine and analogs thereof in biological samples |
CA2721713C (en) | 2008-05-05 | 2019-07-09 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
BRPI0911926A2 (pt) | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
US8790642B2 (en) * | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
GB0818674D0 (en) | 2008-10-10 | 2008-11-19 | Univ Bath | Materials and methods for resolving polyhydric species by electrophoresis |
KR101722423B1 (ko) | 2008-10-20 | 2017-04-18 | 애브비 인코포레이티드 | 항체 정제 동안의 바이러스 불활성화 |
AU2009307728B2 (en) | 2008-10-20 | 2014-12-11 | Abbvie Inc. | Antibodies that bind to IL-18 and methods of purifying the same |
EP2921501A1 (en) | 2008-10-20 | 2015-09-23 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
CN102257004A (zh) | 2008-10-20 | 2011-11-23 | 雅培制药有限公司 | 与il-12结合的抗体及其纯化方法 |
CN101979404B (zh) | 2008-12-09 | 2015-01-14 | 厦门大学 | H5亚型禽流感病毒保守中和表位模拟肽及其用途 |
FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
WO2011010940A1 (en) | 2009-07-19 | 2011-01-27 | Serguei Zavtrak | Solar electric power generator |
CN102712691A (zh) | 2009-08-06 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 蛋白质纯化中提高病毒去除的方法 |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
UA109884C2 (uk) | 2009-10-16 | 2015-10-26 | Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування | |
MX2012004711A (es) * | 2009-10-20 | 2012-05-23 | Abbott Lab | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a. |
TR201806936T4 (tr) | 2010-01-29 | 2018-06-21 | Chugai Pharmaceutical Co Ltd | Anti-dll3 antikoru. |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
SG183847A1 (en) | 2010-03-04 | 2012-10-30 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
SG185583A1 (en) | 2010-05-17 | 2012-12-28 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
CA3209878A1 (en) | 2010-05-25 | 2011-12-01 | Genentech, Inc. | Methods of purifying polypeptides |
AU2011276285A1 (en) | 2010-07-06 | 2013-01-24 | Aveo Pharmaceuticals, Inc. | Anti-RON antibodies |
NZ606357A (en) | 2010-07-30 | 2015-05-29 | Genentech Inc | Safe and functional humanized anti beta-amyloid antibody |
CN104945505A (zh) | 2010-09-29 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | 抗体组合物及使用方法 |
TW201305200A (zh) * | 2010-11-30 | 2013-02-01 | Genentech Inc | 低親和力血腦障壁受體抗體及其用途 |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
EP2773439A4 (en) * | 2011-10-31 | 2015-07-01 | Merck Sharp & Dohme | CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES |
MX363226B (es) * | 2011-10-31 | 2019-03-15 | Genentech Inc | Formulaciones de anticuerpos. |
CN104066748A (zh) * | 2011-11-21 | 2014-09-24 | 霍夫曼-拉罗奇有限公司 | 抗c-met抗体的纯化 |
EP2791176B1 (en) | 2011-12-15 | 2018-07-11 | Prestige Biopharma Pte. Ltd. | A method of antibody purification |
WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
EP3255063A3 (en) | 2012-02-29 | 2018-02-07 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
NZ718144A (en) * | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
-
2014
- 2014-09-12 NZ NZ718144A patent/NZ718144A/en unknown
- 2014-09-12 RU RU2016108828A patent/RU2671481C2/ru active
- 2014-09-12 AU AU2014318615A patent/AU2014318615B2/en active Active
- 2014-09-12 WO PCT/US2014/055387 patent/WO2015038888A1/en active Application Filing
- 2014-09-12 JP JP2016542814A patent/JP6751344B2/ja active Active
- 2014-09-12 SG SG10201802525QA patent/SG10201802525QA/en unknown
- 2014-09-12 BR BR112016004413A patent/BR112016004413A2/pt not_active Application Discontinuation
- 2014-09-12 KR KR1020167009338A patent/KR102373930B1/ko active IP Right Grant
- 2014-09-12 SG SG11201601823TA patent/SG11201601823TA/en unknown
- 2014-09-12 CA CA2921999A patent/CA2921999C/en active Active
- 2014-09-12 AR ARP140103417A patent/AR097651A1/es unknown
- 2014-09-12 CN CN201480062008.9A patent/CN105722532A/zh active Pending
- 2014-09-12 MY MYPI2016000437A patent/MY176026A/en unknown
- 2014-09-12 EP EP23215085.4A patent/EP4331605A3/en active Pending
- 2014-09-12 MX MX2016003202A patent/MX2016003202A/es unknown
- 2014-09-12 NZ NZ756750A patent/NZ756750A/en unknown
- 2014-09-12 CA CA3184564A patent/CA3184564A1/en active Pending
- 2014-09-12 EP EP19204770.2A patent/EP3683232A1/en active Pending
- 2014-09-12 EP EP14844960.6A patent/EP3043820A4/en not_active Withdrawn
- 2014-09-12 NZ NZ756749A patent/NZ756749A/en unknown
- 2014-09-12 MY MYPI2019005052A patent/MY193481A/en unknown
- 2014-09-12 KR KR1020227007621A patent/KR102571391B1/ko active IP Right Grant
-
2016
- 2016-02-16 IL IL244149A patent/IL244149A0/en unknown
- 2016-03-09 US US15/065,693 patent/US9920120B2/en active Active
- 2016-03-10 MX MX2021005358A patent/MX2021005358A/es unknown
- 2016-03-10 MX MX2021005364A patent/MX2021005364A/es unknown
- 2016-03-22 ZA ZA2016/01965A patent/ZA201601965B/en unknown
- 2016-12-20 HK HK16114475A patent/HK1225988A1/zh unknown
-
2018
- 2018-02-01 US US15/886,277 patent/US10597446B2/en active Active
- 2018-02-22 US US15/902,145 patent/US10822404B2/en active Active
- 2018-02-22 US US15/902,141 patent/US10494429B2/en active Active
- 2018-02-22 US US15/902,139 patent/US10597447B2/en active Active
- 2018-03-20 ZA ZA2018/01849A patent/ZA201801849B/en unknown
-
2019
- 2019-05-22 JP JP2019095933A patent/JP6982027B2/ja active Active
-
2020
- 2020-01-23 AU AU2020200502A patent/AU2020200502B9/en active Active
- 2020-04-01 AR ARP200100914A patent/AR118560A2/es unknown
- 2020-09-24 US US17/031,468 patent/US11667706B2/en active Active
-
2021
- 2021-02-19 ZA ZA2021/01142A patent/ZA202101142B/en unknown
- 2021-11-18 JP JP2021187608A patent/JP7489953B2/ja active Active
-
2022
- 2022-01-28 ZA ZA2022/01361A patent/ZA202201361B/en unknown
-
2023
- 2023-04-21 US US18/304,936 patent/US20230250165A1/en active Pending
-
2024
- 2024-01-22 JP JP2024007221A patent/JP2024059617A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118560A2 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
ECSP18066138A (es) | Inhibidores de la proteína quinasa 1 que interactua con el receptor | |
CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
BR112018007017A2 (pt) | polipeptídeos | |
CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
EA201490070A1 (ru) | Коантагонисты глюкагонового рецептора/glp-1-рецептора | |
MX2016007063A (es) | Peptidos terapeuticos. | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
EA201391136A1 (ru) | Лиофилизированные составы | |
BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
CL2016002245A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
CR20130632A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
MX2015012812A (es) | Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor. | |
CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
BR112016001876A2 (pt) | composto de benzoxaborol tricíclico, método de preparação e uso do mesmo |